The abstract is read at the publisher; the summary is JClub's.
The FDA approved iberdomide for multiple myeloma using minimal residual disease negativity as the basis, marking a first for the disease.
- Why it matters: Minimal residual disease negativity can serve as a key efficacy signal, and this approval shows how it may be used to support regulatory decisions in multiple myeloma.
- What they did: The FDA’s decision relied on MRD negativity for iberdomide in multiple myeloma, and the approval also highlights a shift toward targeted protein degraders.
- The result: The approval establishes a regulatory pathway in multiple myeloma based on MRD negativity and supports continued clinical development of more potent cereblon E3 ligase modulators.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.